Parkinson's Disease, Therapy with Drugs and Nanotechnology

Year 2022, Volume: 6 Issue: 2, 121 - 131, 15.12.2022

Kaan Küçükoğlu Hayrunnisa Nadaroglu

Abstract

Parkinson's disease (PD) is a disorder that destroys neurons in the extrapyramidal dopaminergic pathway in the brain. In the world, the number of patients with PD is 10 million
now and PD is a disease whose incidence increases with age. In particular, genetic and environmental factors are believed to cause PD. Rigidity in striated muscles, characteristic
tremors and posture disorder are specified as main clinical symptoms of PD. Although radical treatment of PD is not possible today, some drugs that slow the progression of it and effective
on its symptoms are used successfully in the clinic. Among them, the essential drug is levodopa. However, an important disadvantage in the drug treatment of PD is that the
beneficial effects of the drugs decrease over time in long-term use. Moreover, the use of them is associated with serious side effects. Therefore, it is important to develop new treatment
strategies in the treatment of PD. When a great effort continues to discover new drugs having different action mechanisms, it is expected that developed nanotechnology-based drugs for
PD therapy become important, additionally.

Keywords

Parkinson, Symptoms, Therapy, Drug, Nanotechnology, Nanomedicine